早期类风湿关节炎:活性传统治疗与三种生物制剂的IV期随机盲法评估
这项IV期随机、开放标签、盲法评估者研究纳入812例未治疗早期类风湿关节炎患者,比较甲氨蝶呤联合活性传统治疗与三种生物制剂。24周CDAI缓解率分别为42.7%、46.5%、52.0%和42.1%,仅阿巴西普较传统治疗显著提高,但非劣效分析显示传统治疗不劣于certolizumab和tocilizumab。
要点
- 四种方案均实现高缓解率,阿巴西普24周CDAI缓解率52.0%优于传统治疗42.7%。
- 活性传统治疗不劣于certolizumab和tocilizumab,但不劣于阿巴西普的假设未成立。
- 严重不良事件发生率各组相近,阿巴西普组提前停药人数较少。
核心结论
- 四种治疗均获高缓解率,阿巴西普较活性传统治疗CDAI缓解率更高,certolizumab和tocilizumab则未见优势。
- 非劣效分析表明活性传统治疗不劣于certolizumab和tocilizumab,但不劣于阿巴西普。
研究设计与样本
- 812例未治疗早期类风湿关节炎患者按1:1:1:1随机分组,按国家、性别和抗CCP抗体状态分层。
- 所有患者起始甲氨蝶呤,分别联合活性传统治疗、certolizumab pegol、阿巴西普或tocilizumab。
主要发现
- 24周调整CDAI缓解率:活性传统治疗42.7%(95%CI 36.1%至49.3%),certolizumab 46.5%(39.9%至53.1%),阿巴西普52.0%(45.5%至58.6%),tocilizumab 42.1%(35.3%至48.8%)。
- 相对活性传统治疗的绝对差异:certolizumab 3.9%(95%CI -5.5%至13.2%),阿巴西普9.4%(0.1%至18.7%),tocilizumab -0.6%(-10.1%至8.9%)。
- 严重不良事件例数(至少一次事件患者百分比):活性传统治疗13例(5.6%),certolizumab 20例(8.4%),阿巴西普10例(4.9%),tocilizumab 10例(4.9%)。
- 阿巴西普组11例提前停药,其他组为20至23例。
关键数值与推荐
- 主要终点为24周调整CDAI缓解(CDAI≤2.8),以活性传统治疗为参照。
- 非劣效界值为15%(符合方案人群),活性传统治疗对certolizumab和tocilizumab的非劣效成立,对阿巴西普不成立。
临床怎么用
- 对未治疗早期类风湿关节炎,甲氨蝶呤联合活性传统治疗(泼尼松或sulfasalazine联合羟氯喹及关节腔激素)可作为有效方案。
- 若追求更高CDAI缓解率,可考虑甲氨蝶呤联合阿巴西普,但需结合安全性和停药情况个体化决策。
局限性
- 开放标签设计,虽采用盲法评估者,仍可能存在实施偏倚。
- 非劣效分析基于符合方案人群,未报告意向性分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate and compare benefits and harms of three biological treatments with different modes of action versus active conventional treatment in patients with early rheumatoid arthritis. DESIGN: Investigator initiated, randomised, open label, blinded assessor, multiarm, phase IV study. SETTING: Twenty nine rheumatology departments in Sweden, Denmark, Norway, Finland, the Netherlands, and Iceland between 2012 and 2018. PARTICIPANTS: Patients aged 18 years and older with treatment naive rheumatoid arthritis, symptom duration less than 24 months, moderate to severe disease activity, and rheumatoid factor or anti-citrullinated protein antibody positivity, or increased C reactive protein. INTERVENTIONS: Randomised 1:1:1:1, stratified by country, sex, and anti-citrullinated protein antibody status. All participants started methotrexate combined with (a) active conventional treatment (either prednisolone tapered to 5 mg/day, or sulfasalazine combined with hydroxychloroquine and intra-articular corticosteroids), (b) certolizumab pegol, (c) abatacept, or (d) tocilizumab. MAIN OUTCOME MEASURES: The primary outcome was adjusted clinical disease activity index remission (CDAI≤2.8) at 24 weeks with active conventional treatment as the reference. Key secondary outcomes and analyses included CDAI remission at 12 weeks and over time, other remission criteria, a non-inferiority analysis, and harms. RESULTS: 812 patients underwent randomisation. The mean age was 54.3 years (standard deviation 14.7) and 68.8% were women. Baseline disease activity score of 28 joints was 5.0 (standard deviation 1.1). Adjusted 24 week CDAI remission rates were 42.7% (95% confidence interval 36.1% to 49.3%) for active conventional treatment, 46.5% (39.9% to 53.1%) for certolizumab pegol, 52.0% (45.5% to 58.6%) for abatacept, and 42.1% (35.3% to 48.8%) for tocilizumab. Corresponding absolute differences were 3.9% (95% confidence interval -5.5% to 13.2%) for certolizumab pegol, 9.4% (0.1% to 18.7%) for abatacept, and -0.6% (-10.1% to 8.9%) for tocilizumab. Key secondary outcomes showed no major differences among the four treatments. Differences in CDAI remission rates for active conventional treatment versus certolizumab pegol and tocilizumab, but not abatacept, remained within the prespecified non-inferiority margin of 15% (per protocol population). The total number of serious adverse events was 13 (percentage of patients who experienced at least one event 5.6%) for active conventional treatment, 20 (8.4%) for certolizumab pegol, 10 (4.9%) for abatacept, and 10 (4.9%) for tocilizumab. Eleven patients treated with abatacept stopped treatment early compared with 20-23 patients in the other arms. CONCLUSIONS: All four treatments achieved high remission rates. Higher CDAI remission rate was observed for abatacept versus active conventional treatment, but not for certolizumab pegol or tocilizumab versus active conventional treatment. Other remission rates were similar across treatments. Non-inferiority analysis indicated that active conventional treatment was non-inferior to certolizumab pegol and tocilizumab, but not to abatacept. The results highlight the efficacy and safety of active conventional treatment based on methotrexate combined with corticosteroids, with nominally better results for abatacept, in treatment naive early rheumatoid arthritis. TRIAL REGISTRATION: EudraCT2011-004720-35, NCT01491815.
引用
- Hetland ML, Haavardsholm EA, Rudin A, et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ. 2020. PMID: 33268527. doi:10.1136/bmj.m4328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。